TY - JOUR
T1 - High-density lipoprotein-cholesterol functionality and metabolic syndrome
T2 - Protocol for review and meta-analysis
AU - Roever, Leonardo
AU - Resende, Elmiro Santos
AU - Diniz, Angélica Lemos Debs
AU - Penha-Silva, Nilson
AU - O'Connell, João Lucas
AU - Gomes, Paulo Fernando Silva
AU - Zanetti, Hugo Ribeiro
AU - Roerver-Borges, Anaisa Silva
AU - Veloso, Fernando César
AU - De Souza, Fernanda Rodrigues
AU - Duarte, Poliana Rodrigues Alves
AU - Fidale, Thiago Montes
AU - Casella-Filho, Antonio
AU - Dourado, Paulo Magno Martins
AU - Chagas, Antonio Carlos Palandri
AU - Ali-Hasan-Al-Saegh, Sadeq
AU - Reis, Paulo Eduardo Ocke
AU - De Melo Costa Pinto, Rogério
AU - Oliveira, Gustavo B.F.
AU - Avezum, Álvaro
AU - Neto, Mansueto
AU - Durães, André Rodrigues
AU - Da Silva, Rose Mary Ferreira Lisboa
AU - Grande, Antonio José
AU - Denardi, Celise
AU - Lopes, Renato Delascio
AU - Nerlekar, Nitesh
AU - Alizadeh, Shahab
AU - Hernandez, Adrian V.
AU - Da Rosa, Maria Inês
AU - Biondi-Zoccai, Giuseppe
AU - for the Brazilian Network of Research in Meta-analysis (BRAMETIS)
PY - 2018/6
Y1 - 2018/6
N2 - Introduction: The prevalence of metabolic syndrome (MetS) and MetS-related stroke is set to increase dramatically in coming decades. MetS is a complex disease that includes endothelial dysfunction, insulin resistance, diabetes, hypertension, ectopic obesity, and dyslipidaemia and an increased risk of cardiovascular events. One function of high-density lipoprotein (HDL) cholesterol (HDL-C) is the cholesterol-efflux pathway, which is the pathway where cholesterol is removed from macrophages within the arterial walls back into the bloodstream and out to the liver. As one of the key functions of HDL, their hypothesis was that if they could measure HDL-C-efflux capacity, they would have a better handle on the role of HDL in atherosclerosis. However, there are no systematic analyses or well-conducted meta-analyses to evaluate the relationship between HDL-C functionality and MetS. The aim of this study is to examine this association of HDL-C functionality with MetS in different ages and sex. Methods and analysis: The update systematic review and meta-analysis will be conducted using published studies that will be identified from electronic databases (i.e., PubMed, EMBASE, Web of Science, and Google Scholar). Studies that examined the association between HDL-C functionality and MetS; focused on cohort, case-control, and cross-sectional studies; were conducted among in adults aged 40 to 70 years; provided sufficient data for calculating odds ratio or relative risk with a 95% confidence interval; were published as original articles written in English or other languages; and have been published until January 2018 will be included. Study selection, data collection, quality assessment, and statistical syntheses will be conducted based on discussions among investigators. Ethics and dissemination: Ethics approval was not required for this study because it was based on published studies. The results and findings of this study will be submitted and published in a scientific peer-reviewed journal.
AB - Introduction: The prevalence of metabolic syndrome (MetS) and MetS-related stroke is set to increase dramatically in coming decades. MetS is a complex disease that includes endothelial dysfunction, insulin resistance, diabetes, hypertension, ectopic obesity, and dyslipidaemia and an increased risk of cardiovascular events. One function of high-density lipoprotein (HDL) cholesterol (HDL-C) is the cholesterol-efflux pathway, which is the pathway where cholesterol is removed from macrophages within the arterial walls back into the bloodstream and out to the liver. As one of the key functions of HDL, their hypothesis was that if they could measure HDL-C-efflux capacity, they would have a better handle on the role of HDL in atherosclerosis. However, there are no systematic analyses or well-conducted meta-analyses to evaluate the relationship between HDL-C functionality and MetS. The aim of this study is to examine this association of HDL-C functionality with MetS in different ages and sex. Methods and analysis: The update systematic review and meta-analysis will be conducted using published studies that will be identified from electronic databases (i.e., PubMed, EMBASE, Web of Science, and Google Scholar). Studies that examined the association between HDL-C functionality and MetS; focused on cohort, case-control, and cross-sectional studies; were conducted among in adults aged 40 to 70 years; provided sufficient data for calculating odds ratio or relative risk with a 95% confidence interval; were published as original articles written in English or other languages; and have been published until January 2018 will be included. Study selection, data collection, quality assessment, and statistical syntheses will be conducted based on discussions among investigators. Ethics and dissemination: Ethics approval was not required for this study because it was based on published studies. The results and findings of this study will be submitted and published in a scientific peer-reviewed journal.
KW - Lipids
KW - Metabolic syndrome
KW - Systematic review
UR - http://www.scopus.com/inward/record.url?scp=85049410132&partnerID=8YFLogxK
U2 - 10.1097/MD.0000000000011094
DO - 10.1097/MD.0000000000011094
M3 - Review Article
C2 - 29901625
AN - SCOPUS:85049410132
VL - 97
JO - Medicine®
JF - Medicine®
SN - 0025-7974
IS - 24
M1 - e1094
ER -
